IDYA — Ideaya Biosciences Cashflow Statement
0.000.00%
- $1.66bn
- $986.89m
- $7.00m
Annual cashflow statement for Ideaya Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -34.5 | -49.8 | -58.7 | -113 | -274 |
Depreciation | |||||
Non-Cash Items | 4.17 | 10.1 | 12.3 | 8.47 | 13 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 84.4 | -17.8 | -43 | -13.2 | 11.5 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | 55.5 | -55.8 | -87.2 | -115 | -248 |
Capital Expenditures | -0.493 | -2.64 | -3.44 | -2.37 | -3.86 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -146 | -67 | -30 | -156 | -499 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -146 | -69.7 | -33.4 | -158 | -503 |
Financing Cash Flow Items | 20 | 0 | 0 | — | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Cash from Financing Activities | 129 | 145 | 97.2 | 363 | 678 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 38 | 20 | -23.4 | 89 | -72.6 |